KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Cash from Investing Activities (2016 - 2025)

Evolent Health (EVH) has 11 years of Cash from Investing Activities data on record, last reported at $82.2 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 512.21% year-over-year to $82.2 million; the TTM value through Dec 2025 reached -$233000.0, up 99.63%, while the annual FY2025 figure was -$233000.0, 99.63% up from the prior year.
  • Cash from Investing Activities reached $82.2 million in Q4 2025 per EVH's latest filing, up from -$8.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $82.2 million in Q4 2025 and bottomed at -$395.0 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is -$37.7 million, with a median of -$9.2 million recorded in 2024.
  • Peak YoY movement for Cash from Investing Activities: soared 525.2% in 2021, then tumbled 14081.81% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$54.4 million in 2021, then surged by 91.8% to -$4.5 million in 2022, then crashed by 35.82% to -$6.1 million in 2023, then crashed by 229.31% to -$19.9 million in 2024, then skyrocketed by 512.21% to $82.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $82.2 million in Q4 2025, -$8.8 million in Q3 2025, and -$60.5 million in Q2 2025.